The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer

Journal of Endocrinology

Volumn 178, Issue 2, 2003, Pages 205-216

  Mitsiades, C S ^b   Poulaki, V ^a   Mitsiades, N ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYL AMINOGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; CASPASE INHIBITOR; CELL SURFACE RECEPTOR; CYCLOHEXIMIDE; CYTOKINE; FAS LIGAND; GAMMA INTERFERON; GELDANAMYCIN; GROWTH FACTOR; INTERLEUKIN 1BETA; LIGAND; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL DEATH; CELL KILLING; CELL MEDIATED CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; IMMUNE SYSTEM; MICROENVIRONMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THYROID CANCER; THYROID CELL; UPREGULATION;

ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BACTERIAL PROTEINS; CELL COMMUNICATION; FAS LIGAND PROTEIN; HUMANS; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; TH1 CELLS; THYROID NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042855004     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1780205     Document Type: Review

References (110)

1. Adams JM & Cory S 1998 The Bcl-2 protein family: arbiters of cell survival. Science 281 1322-1326.
2. Ahmad M & Shi Y 2000 TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene 19 3363-3371.
3. Akslen LA & Varhaug JE 1995 Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 76 1643-1654.
4. Akslen LA, Myking AO, Salvesen H & Varhaug JE 1993 Prognostic impact of EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer 68 808-812.
5. Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M & Rustgi AK 2003 Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. Journal of Biological Chemistry 278 1824-1830.
6. Andrikoula M & Tsatsoulis A 2001 The role of Fas-mediated apoptosis in thyroid disease. European Journal of Endocrinology 144 561-568.
7. Andrikoula M, Vartholomatos G, Tsangaris GT, Bafa M, Tzortzatou-Stathopoulou F & Tsatsoulis A 2001 Fas and Bcl-2 protein expression in thyrocytes of patients with nodular goiter. European Journal of Endocrinology 145 403-407.
8. Arscott PL & Baker JR Jr 1998 Apoptosis and thyroiditis. Clinical Immunology and Immunopathology 87 207-217.
9. Arscott PL, Knapp J, Rymaszewski M, Bartron JL, Bretz JD, Thompson NW & Baker JR Jr 1997 Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor. Endocrinology 138 5019-5027.
10. Arscott PL, Stokes T, Myc A, Giordano TJ, Thompson NW & Baker JR Jr 1999 Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 84 4246-4252.
11. Ashkenazi A & Dixit VM 1998 Death receptors: signaling and modulation. Science 281 1305-1308.
12. Ashkenazi A & Dixit VM 1999 Apoptosis control by death and decoy receptors. Current Opinion in Cell Biology 11 255-260.
13. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A et al. 1999 Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Investigation 104 155-162.
14. Aust G, Heuer M, Laue S, Lehmann I, Hofmann A, Heldin NE & Scherbaum WA 1996 Expression of tumour necrosis factor-alpha (TNF-alpha) mRNA and protein in pathological thyroid tissue and carcinoma cell lines. Clinical and Experimental Immunology 105 148-154.
15. Baker JR, Jr 1995 The immune response to papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 80 3419-3420.
16. Baker JR, Jr 1999 Dying (apoptosing?) for a consensus on the Fas death pathway in the thyroid. Clinical Endocrinology and Metabolism 84 2593-2595.
17. Basolo F, Pollina L, Fontanini G, Fiore L, Pacini F & Baldanzi A 1997 Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. British Journal of Cancer 75 537-541.
18. Basso AD, Solit DB, Munster PN & Rosen N 2002 Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21 1159-1166.
19. Borgerson KL, Bretz JD & Baker JR Jr 1999 The role of Fas-mediated apoptosis in thyroid autoimmune disease. Autoimmunity 30 251-264.
20. Bretz JD, Arscott PL, Myc A, Baker JR Jr 1999a Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells. Journal of Biological Chemistry 274 25433-25438.
21. Bretz JD, Rymaszewski M, Arscott PL, Myc A, Ain KB, Thompson NW & Baker JR Jr 1999b TRAIL death pathway expression and induction in thyroid follicular cells. Journal of Biological Chemistry 274 23627-23632.
22. Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW & Baker JR Jr 2002 Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death and Differentiation 9 274-286.
23. Chen Y, Li X, Eswarakumar VP, Seger R & Lonai P 2000 Fibroblast growth factor (FGF) signaling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation. Oncoqene 19 3750-3756.
24. Coultas L & Strasser A 2003 The role of the Bcl-2 protein family in cancer. Seminars in Cancer Biology 13 115-123.
25. Daa T, Kodama M, Kashima K, Yokoyama S, Nakayama I & Noguchi S 1993 Identification of basic fibroblast growth factor in papillary carcinoma of the thyroid. Acta Pathologica Japonica 43 582-589.
26. De Vita G, Berlingieri MT, Visconti R, Castellone MD, Viglietto G, Baldassarre G, Zannini M, Bellacosa A, Tsichlis PN, Fusco A et al. 2000 Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. Cancer Research 60 3916-3920.
27. Denmeade SR, Lin XS & Isaacs JT 1996 Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. [Erratum appears in Prostate 1996 28 414.] Prostate 28 251-265.
28. Dunn FB 2002 Heat shock protein inhibitor shows antitumor activity. JNCI Cancer Spectrum 94 1194-1195.
29. Eggo MC, Hopkins JM, Franklyn JA, Johnson GD, Sanders DS & Sheppard MC 1995 Expression of fibroblast growth factors in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 80 1006-1011.
30. Fotin-Mleczek M, Henkler F, Samel D, Reichwein M, Hausser A, Parmryd I, Scheurich P, Schmid JA & Wajant H 2002 Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. Journal of Cell Science 115 2757-2770.
31. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R & Galluzzo A 1997 Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275 960-963.
32. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P & Ohgaki H 1997 Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathology 7 863-869.
33. Gratas C, Tohma Y, Barnas C, Tainere P, Hainaut P & Ohgaki H 1998 Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Research 58 2057-2062.
34. Gruss H 1996 Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. International Journal of Clinical and Laboratory Research 26 143-159.
35. Haanen C & Vermes I 1996 Apoptosis: programmed cell death in fetal development. European Journal of Obstetrics, Gynecology, and Reproductive Biology 64 129-133.
36. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D et al. 1996 Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274 1363-1366.
37. Hammond LJ, Lowdell MW, Cerrano PG, Goode AW, Bottazzo GF & Mirakian R 1997 Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. Journal of Pathology 182 138-144.
38. Hoelting T, Siperstein AE, Clark OH & Duh QY 1994 Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo. Journal of Clinical Endocrinology and Metabolism 79 401-408.
39. Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, Orringer MB & Beer DG 1997 Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Research 57 5571-5578.
40. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C et al. 1997 Inhibition of death receptor signals by cellular FLIP. Nature 388 190-195.
41. Jin Z & El-Deiry WS 2001 Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Proceedings of the American Association for Cancer Research 42 438.
42. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR & Strom SC 2000 Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature Medicine 6 564-567.
43. Jupp OJ, McFarlane SM, Anderson HM, Littlejohn AF, Mohamed AA, MacKay RH, Vandenabeele P & MacEwan DJ 2001 Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. Biochemical Journal 359 525-535.
44. Kanamori A, Abe Y, Yajima Y, Manabe Y & Ito K 1989 Epidermal growth factor receptors in plasma membranes of normal and diseased human thyroid glands. Journal of Clinical Endocrinology and Metabolism 68 899-903.
45. Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Kawabe Y, Ishikawa N, Ito K & Nagataki S 1996 Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology 137 3163-3169.
46. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ & Ashkenazi A 2000 Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 611-620.
47. Kodama M, Daa T, Kashima K, Yokoyama S, Nakayama I & Noguchi S 1994 Immunohistochemical localization of acidic and basic fibroblast growth factors in human benign and malignant thyroid lesions. Japanese Journal of Clinical Oncology 24 66-73.
48. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P et al. 2001 Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nature Medicine 7 383-385.
49. Lebedeva IV, Su Z-Z, Sarkar D & Fisher PB 2003 Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Seminars in Cancer Biology 13 169-178.
50. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH & Moller P 1993 Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Laboratory Investigation 69 415-429.
51. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M et al. 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group [Comment]. New England Journal of Medicine 343 1594-1602.
52. Madge LA & Pober JS 2001 TNF signaling in vascular endothelial cells. Experimental and Molecular Pathology 70 317-325.
53. Makinen T, Pekonen F, Franssila K & Lamberg BA 1988 Receptors for epidermal growth factor and thyrotropin in thyroid carcinoma. Acta Endocrinologica 117 45-50.
54. Mezosi E, Yamazaki H, Bretz JD, Wang SH, Arscott PL, Utsugi S, Gauger PG, Thompson NW & Baker JR Jr 2002 Aberrant apoptosis in thyroid epithelial cells from goiter nodules. Journal of Clinical Endocrinology and Metabolism 87 4264-4272.
55. Mitsiades N, Poulaki V, Kotoula V, Leone A & Tsokos M 1998a Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. American Journal of Pathology 153 1947-1956.
56. Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tseleni-Balafouta S, Koutras DA & Tsokos M 1998b Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. Journal of Clinical Endocrinology and Metabolism 83 2199-2203.
57. Mitsiades N, Poulaki V, Leone A & Tsokos M 1999a Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. Journal of the National Cancer Institute 91 1678-1684.
58. Mitsiades N, Poulaki V, Mastorakos G, Tseleni-Balafouta ST, Kotoula V, Koutras DA & Tsokos M 1999b Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. Journal of Clinical Endocrinology and Metabolism 84 2924-2932.
59. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA & Stamenkovic I 2000 Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Research 60 4122-4129.
60. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T & Anderson KC 2001a TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98 795-804.
61. Mitsiades N, Poulaki V, Mitsiades C & Tsokos M 2001b Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and express DR4 and DR5 receptors. Cancer Research 61 2704-2712.
62. Mitsiades N, Poulaki V, Mitsiades CS, Koutras DA & Chrousos GP 2001c Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends in Endocrinology and Metabolism 12 384-390.
63. Mitsiades N, Yu WH, Poulaki V, Tsokos M & Stamenkovic I 2001d Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Research 61 577-581.
64. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG et al. 2002 Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-I/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21 5673-5683.
65. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D et al. 1997 Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. [Erratum appears in Nature 1997 386 738.] Nature 385 733-736.
66. Munster PN, Srethapakdi M, Moasser MM & Rosen N 2001 Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Research 61 2945-2952.
67. Muschen M, Warskulat U & Beckmann MW 2000 Defining CD95 as a tumor suppressor gene. Journal of Molecular Medicine 78 312-325.
68. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS & Dixit VM 1998 An induced proximity model for caspase-8 activation. Journal of Biological Chemistry 273 2926-2930.
69. Myc A, Arscott PL, Bretz JD, Thompson NW & Baker JR Jr 1999 Characterization of FAP-1 expression and function in thyroid follicular cells. Endocrinology 140 5431-5434.
70. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB & Beer DG 1998 Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. Journal of Clinical Investigation 101 1102-1110.
71. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp PJ, Green DR & Kratzke RA 1997 Human lung carcinomas express Fas ligand. Cancer Research 57 1007-1012.
72. O'Connell J, O'Sullivan GC, Collins JK & Shanahan F 1996 The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. Journal of Experimental Medicine 184 1075-1082.
73. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T & Nagata S 1993 Lethal effect of the anti-Fas antibody in mice. Nature 364 806-809.
74. Ohta K, Pang XP, Berg L & Hershman JM 1996 Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism 81 2607-2612.
75. Ozoren N & El-Deiry WS 2003 Cell surface death receptor signaling in normal and cancer cells. Seminars in Cancer Biology 13 135-147.
76. Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD & El-Deiry WS 2000 The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Research 60 6259-6265.
77. Pang XP, Hershman JM, Chung M & Pekary AE 1989 Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 125 1783-1788.
78. Pang XP, Ross NS, Park M, Juillard GJ, Stanley TM & Hershman JM 1992 Tumor necrosis factor-alpha activates nuclear factor kappa B and induces manganous superoxide dismutase and phosphodiesterase mRNA in human papillary thyroid carcinoma cells. Journal of Biological Chemistry 267 12826-12830.
79. Pang XP, Ross NS & Hershman JM 1996 Alterations in TNF-alpha signal transduction in resistant human papillary thyroid carcinoma cells. Thyroid 6 313-317.
80. Pang XP, Hershman JM & Karsan A 1997 TNF-alpha induction of A1 expression in human cancer cells. Oncology Research 9 623-627.
81. Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA & Mitsiades N 2002 Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. American Journal of Pathology 161 643-654.
82. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL et al. 1999 Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine 340 1398-1405.
83. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC & Whiteside TL 1998 Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. Journal of Clinical Investigation 101 2579-2588.
84. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD & Saji M 2001 Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Research 61 6105-6111.
85. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J & Dietrich PY 1997 Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? Journal of Clinical Investigation 99 1173-1178.
86. Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I, Hirai A, Suzuki K, Kohn LD, Saji M & Ringel MD 2001 Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 11 339-351.
87. Salcedo TW, Alderson RF, Basu S, Beatty S, Choi GH, Corcoran M, Halpern W, Gentz S, Gregorio T, Grzegorzewski KJ, Kanakaraj P. 2002 TRM-1, a fully human TRAIL-R1 agonistic monoclonal antibody, displays in vitro and in vivo anti-tumor activity. Proceedings of the American Association for Cancer Research 43 856.
88. Salvesen GS & Dixit VM 1999 Caspase activation: the induced-proximity model. PNAS 96 10964-10967.
89. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S & Peter ME 1998 Apoptosis signaling by death receptors. European Journal of Biochemistry 254 439-459.
90. Shingu K, Sugenoya A, Itoh N & Kato R 1994 Expression of basic fibroblast growth factor in thyroid disorders. World Journal of Surgery 18 500-505.
91. Shingu K, Fujimori M, Ito K, Hama Y, Kasuga Y, Kobayashi S, Itoh N & Amano J 1998 Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions. Endocrine Journal 45 35-43.
92. Simpson SQ & Casey LC 1989 Role of tumor necrosis factor in sepsis and acute lung injury. Critical Care Clinics 5 27-47.
93. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo, P, Blenis J, Krammer PH & Walczak H 2000 FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 599-609.
94. Stassi G & De Maria R 2002 Autoimmune thyroid disease: new models of cell death in autoimmunity. Nature Reviews. Immunology 2 195-204.
95. Stassi G, Di Liberto D, Todaro M, Zeuner A, Ricci-Vitiani L, Stoppacciaro A, Ruco L, Farina F, Zummo G & De Maria R 2000 Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nature Immunology 1 483-488.
96. Tanimoto C, Hirakawa S, Kawasaki H, Hayakawa N & Ota Z 1995 Apoptosis in thyroid diseases: a histochemical study. Endocrine Journal 42 193-201.
97. Tartaglia LA, Pennica D & Goeddel DV 1993 Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. Journal of Biological Chemistry 268 18542-18548.
98. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M et al. 1997 Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386 517-521.
99. Thompson CB 1995 Apoptosis in the pathogenesis and treatment of disease. Science 267 1456-1462.
100. Tracey KJ 1991 Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. Circulatory Shock 35 123-128.
101. Tsatsoulis A 2002 The role of apoptosis in thyroid disease. Minerva Medica 93 169-180.
102. van der Laan BF, Freeman JL & Asa SL 1995 Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5 67-73.
103. Vella V, Sciacca L, Pandini G, Mineo K, Squatrito S, Vigneri R & Belfiore A 2001 The IGF system in thyroid cancer: new concepts. Molecular Pathology 54 121-124.
104. Vinay DS & Kwon BS 1998 Role of 4-1BB in immune responses. Seminars in Immunology 10 481-489.
105. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T et al. 1999 Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Medicine 5 157-163.
106. Wang CY, Zhong WB, Chang TC, Lai SM & Tsai YF 2002 Tumor necrosis factor alpha induces three-dimensional cytomorphologic differentiation of human anaplastic thyroid carcinoma cells through activation of nuclear factor kappaB. Cancer 95 1827-1833.
107. Weetman AP & McGregor AM 1994 Autoimmune thyroid disease: further developments in our understanding. Endocrine Reviews 15 788-830.
108. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M & Burge DJ 1999 A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [Comment]. New England Journal of Medicine 340 253-259.
109. Westermark K, Lundqvist M, Wallin G, Dahlman T, Hacker GW, Heldin NE & Grimelius L 1996 EGF-receptors in human normal and pathological thyroid tissue. Histopathology 28 221-227.
110. Zhivotovsky B & Orrenius S 2003 Defects in the apoptotic machinery of cancer cells: role in drug resistance. Seminars in Cancer Biology 13 125-134.